Skip to main content
Top
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Antibiotic | Research

Gram-negative bacterial colonizations before bilateral lung transplant. The impact of ‘targeted’ versus ‘standard’ surgical prophylaxis

Authors: Sabrina Congedi, Arianna Peralta, Luisa Muraro, Martina Biscaro, Tommaso Pettenuzzo, Nicolò Sella, Silvia Crociani, Arméla Anne-Sabine Tagne, Ida Caregnato, Francesco Monteleone, Elisa Rossi, Gabriella Roca, Silvia Manfrin, Serena Marinello, Maria Mazzitelli, Andrea Dell’Amore, Annamaria Cattelan, Federico Rea, Paolo Navalesi, Annalisa Boscolo

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Background

Infections are one of the most common causes of death after lung transplant (LT). However, the benefit of ‘targeted’ prophylaxis in LT recipients pre-colonized by Gram-negative (GN) bacteria is still unclear.

Methods

All consecutive bilateral LT recipients admitted to the Intensive Care Unit of the University Hospital of Padua (February 2016–2023) were retrospectively screened. Only patients with pre-existing GN bacterial isolations were enrolled and analyzed according to the antimicrobial surgical prophylaxis (‘standard’ vs. ‘targeted’ on the preoperative bacterial isolation).

Results

One hundred eighty-one LT recipients were screened, 46 enrolled. Twenty-two (48%) recipients were exposed to ‘targeted’ prophylaxis, while 24 (52%) to ‘standard’ prophylaxis. Overall prevalence of postoperative multi-drug resistant (MDR) GN bacteria isolation was 65%, with no differences between the two surgical prophylaxis (p = 0.364). Eleven (79%) patients treated with ‘standard’ prophylaxis and twelve (75%) with ‘targeted’ therapy reconfirmed the preoperative GN pathogen (p = 0.999). The prevalence of postoperative infections due to MDR GN bacteria was 50%. Of these recipients, 4 belonged to the ‘standard’ and 11 to the ‘targeted’ prophylaxis (p = 0.027).

Conclusions

The administration of a ‘targeted’ prophylaxis in LT pre-colonized recipients seemed not to prevent the occurrence of postoperative MDR GN infections.
Appendix
Available only for authorised users
Literature
1.
go back to reference Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D, Hsich E. etal.The international thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report– 2019; focus theme: Donor and recipient size match.J Heart Lung Transplant Off Publ Int Soc Heart Transplant.2019;38(10):1056–66. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D, Hsich E. etal.The international thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report– 2019; focus theme: Donor and recipient size match.J Heart Lung Transplant Off Publ Int Soc Heart Transplant.2019;38(10):1056–66.
3.
go back to reference Congedi S, Navalesi P, Boscolo A. Multidrug-resistant organisms in lung transplant: a narrative review.Curr Opin Organ Transplant.2023. Congedi S, Navalesi P, Boscolo A. Multidrug-resistant organisms in lung transplant: a narrative review.Curr Opin Organ Transplant.2023.
4.
go back to reference Lanini S, Costa AN, Puro V, Procaccio F, Grossi PA, Vespasiano F. etal.Incidence of carbapenem-resistant gram negatives in Italian transplant recipients: a nationwide surveillance study.PloS One.2015;10(4):e0123706. Lanini S, Costa AN, Puro V, Procaccio F, Grossi PA, Vespasiano F. etal.Incidence of carbapenem-resistant gram negatives in Italian transplant recipients: a nationwide surveillance study.PloS One.2015;10(4):e0123706.
5.
go back to reference Tebano G, Geneve C, Tanaka S, Grall N, Atchade E, Augustin P. Epidemiology and risk factors of multidrug-resistant bacteria in respiratory samples after lung transplantation. Transpl Infect Dis off J Transpl Soc. 2016;18(1):22–30.CrossRef Tebano G, Geneve C, Tanaka S, Grall N, Atchade E, Augustin P. Epidemiology and risk factors of multidrug-resistant bacteria in respiratory samples after lung transplantation. Transpl Infect Dis off J Transpl Soc. 2016;18(1):22–30.CrossRef
6.
go back to reference Boscolo A, Sella N, Pettenuzzo T, De Cassai A, Crociani S, Schiavolin C. etal.Multidrug-resistant and extended-spectrum β-Lactamase gram-negative Bacteria in bilateral lung transplant recipients: incidence, risk factors, and In-Hospital mortality.Chest. 2022;162(6):1255–64. Boscolo A, Sella N, Pettenuzzo T, De Cassai A, Crociani S, Schiavolin C. etal.Multidrug-resistant and extended-spectrum β-Lactamase gram-negative Bacteria in bilateral lung transplant recipients: incidence, risk factors, and In-Hospital mortality.Chest. 2022;162(6):1255–64.
7.
go back to reference Paglicci L, Borgo V, Lanzarone N, Fabbiani M, Cassol C, Cusi MG. etal.Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients.Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol.2021;40(6):1271–82. Paglicci L, Borgo V, Lanzarone N, Fabbiani M, Cassol C, Cusi MG. etal.Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients.Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol.2021;40(6):1271–82.
8.
go back to reference Boscolo A, Dell’Amore A, Pettenuzzo T, Sella N, De Cassai A, Pistollato E. etal.The impact of New treatments on short- and MID-Term outcomes in bilateral lung transplant: a propensity score study.J Clin Med. 2022;11(19):5859. Boscolo A, Dell’Amore A, Pettenuzzo T, Sella N, De Cassai A, Pistollato E. etal.The impact of New treatments on short- and MID-Term outcomes in bilateral lung transplant: a propensity score study.J Clin Med. 2022;11(19):5859.
9.
go back to reference Chung PA, Dilling DF. Immunosuppressive strategies in lung transplantation.Ann Transl Med. 2020;8(6):409. Chung PA, Dilling DF. Immunosuppressive strategies in lung transplantation.Ann Transl Med. 2020;8(6):409.
10.
go back to reference Ivulich S, Westall G, Dooley M, Snell G. The evolution of lung transplant immunosuppression.Drugs.2018;78(10):965–82. Ivulich S, Westall G, Dooley M, Snell G. The evolution of lung transplant immunosuppression.Drugs.2018;78(10):965–82.
12.
go back to reference Burguete SR, Maselli DJ, Fernandez JF, Levine SM. Lung transplant infection.Respirol Carlton Vic.2013;18(1):22–38. Burguete SR, Maselli DJ, Fernandez JF, Levine SM. Lung transplant infection.Respirol Carlton Vic.2013;18(1):22–38.
13.
go back to reference Fishman JA. Infection in Organ Transplantation.Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.2017;17(4):856–79. Fishman JA. Infection in Organ Transplantation.Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.2017;17(4):856–79.
14.
go back to reference Remund KF, Best M, Egan JJ. Infections relevant to lung transplantation.Proc Am Thorac Soc2009;6(1):94–100. Remund KF, Best M, Egan JJ. Infections relevant to lung transplantation.Proc Am Thorac Soc2009;6(1):94–100.
15.
go back to reference Coiffard B, Prud’Homme E, Hraiech S, Cassir N, Le Pavec J, Kessler R. etal.Worldwide clinical practices in perioperative antibiotic therapy for lung transplantation.BMC Pulm Med.2020;20(1):109. Coiffard B, Prud’Homme E, Hraiech S, Cassir N, Le Pavec J, Kessler R. etal.Worldwide clinical practices in perioperative antibiotic therapy for lung transplantation.BMC Pulm Med.2020;20(1):109.
16.
go back to reference Oriol I, Sabé N, Simonetti AF, Lladó L, Manonelles A, González J. etal.Changing trends in the etiology, treatment and outcomes of bloodstream infection occurring in the first year after solid organ transplantation: a single-centre prospective cohort study.Transpl Int Off J Eur Soc Organ Transplant.2017;30(9):903–13. Oriol I, Sabé N, Simonetti AF, Lladó L, Manonelles A, González J. etal.Changing trends in the etiology, treatment and outcomes of bloodstream infection occurring in the first year after solid organ transplantation: a single-centre prospective cohort study.Transpl Int Off J Eur Soc Organ Transplant.2017;30(9):903–13.
17.
go back to reference Zenati M, Dowling RD, Dummer JS, Paradis IL, Arena VC, Armitage JM. etal.Influence of the donor lung on development of early infections in lung transplant recipients.J Heart Transplant. 1990;9(5):502–8;discussion 508–509. Zenati M, Dowling RD, Dummer JS, Paradis IL, Arena VC, Armitage JM. etal.Influence of the donor lung on development of early infections in lung transplant recipients.J Heart Transplant. 1990;9(5):502–8;discussion 508–509.
18.
go back to reference Bartoletti M, Giannella M, Tedeschi S, Viale P. Multidrug-resistant bacterial infections in solid organ transplant candidates and recipients. Infect Dis Clin North Am. 2018;32(3):551–80.CrossRefPubMed Bartoletti M, Giannella M, Tedeschi S, Viale P. Multidrug-resistant bacterial infections in solid organ transplant candidates and recipients. Infect Dis Clin North Am. 2018;32(3):551–80.CrossRefPubMed
19.
go back to reference Di Nardo M, Tikkanen J, Husain S, Singer LG, Cypel M, Ferguson ND. etal.Postoperative management of lung transplant recipients in the Intensive Care Unit.Anesthesiology.2022;136(3):482–99. Di Nardo M, Tikkanen J, Husain S, Singer LG, Cypel M, Ferguson ND. etal.Postoperative management of lung transplant recipients in the Intensive Care Unit.Anesthesiology.2022;136(3):482–99.
20.
go back to reference van Duin D, van Delden C. Multidrug-resistant gram-negative Bacteria infections in solid organ transplantation.Am J Transplant.2013;13:31–41. van Duin D, van Delden C. Multidrug-resistant gram-negative Bacteria infections in solid organ transplantation.Am J Transplant.2013;13:31–41.
21.
go back to reference Pouch SM, Patel G, AST Infectious Diseases Community of Practice. Multidrug-resistant Gram-negative bacterial infections in solid organ transplant recipients-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant.2019;33(9):e13594. Pouch SM, Patel G, AST Infectious Diseases Community of Practice. Multidrug-resistant Gram-negative bacterial infections in solid organ transplant recipients-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant.2019;33(9):e13594.
22.
go back to reference Marczin N, de Waal EEC, Hopkins PMA, Mulligan MS, Simon A, Shaw AD. etal.International consensus recommendations for anesthetic and intensive care management of lung transplantation. An EACTAIC, SCA, ISHLT, ESOT, ESTS, and AST approved document.J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2021;40(11):1327–48. Marczin N, de Waal EEC, Hopkins PMA, Mulligan MS, Simon A, Shaw AD. etal.International consensus recommendations for anesthetic and intensive care management of lung transplantation. An EACTAIC, SCA, ISHLT, ESOT, ESTS, and AST approved document.J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2021;40(11):1327–48.
23.
go back to reference Aguado JM, Silva JT, Fernández-Ruiz M, Cordero E, Fortún J, Gudiol C. etal.Management of multidrug resistant gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.Transplant Rev Orlando Fla.2018;32(1):36–57. Aguado JM, Silva JT, Fernández-Ruiz M, Cordero E, Fortún J, Gudiol C. etal.Management of multidrug resistant gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.Transplant Rev Orlando Fla.2018;32(1):36–57.
24.
go back to reference Cervera C, van Delden C, Gavaldà J, Welte T, Akova M, Carratalà J. etal.Multidrug-resistant bacteria in solid organ transplant recipients. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.2014;20 Suppl 7:49–73. Cervera C, van Delden C, Gavaldà J, Welte T, Akova M, Carratalà J. etal.Multidrug-resistant bacteria in solid organ transplant recipients. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.2014;20 Suppl 7:49–73.
25.
go back to reference Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M. The Third International Consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.CrossRefPubMedPubMedCentral Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M. The Third International Consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.CrossRefPubMedPubMedCentral
26.
go back to reference Cuschieri S. The STROBE guidelines. Saudi J Anaesth.2019;13(Suppl 1):S31–4. Cuschieri S. The STROBE guidelines. Saudi J Anaesth.2019;13(Suppl 1):S31–4.
28.
go back to reference Timsit JF, Huntington JA, Wunderink RG, Shime N, Kollef MH, Kivistik Ü. etal.Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.Crit Care Lond Engl.2021;25(1):290. Timsit JF, Huntington JA, Wunderink RG, Shime N, Kollef MH, Kivistik Ü. etal.Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.Crit Care Lond Engl.2021;25(1):290.
29.
go back to reference Klompas M, Branson R, Cawcutt K, Crist M, Eichenwald EC, Greene LR. etal.Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 update.Infect Control Hosp Epidemiol.2022;43(6):687–713. Klompas M, Branson R, Cawcutt K, Crist M, Eichenwald EC, Greene LR. etal.Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 update.Infect Control Hosp Epidemiol.2022;43(6):687–713.
30.
go back to reference Mahajan AK, Folch E, Khandhar SJ, Channick CL, Santacruz JF, Mehta AC. The diagnosis and management of Airway complications following lung transplantation. Chest. 2017;152(3):627–38.CrossRefPubMed Mahajan AK, Folch E, Khandhar SJ, Channick CL, Santacruz JF, Mehta AC. The diagnosis and management of Airway complications following lung transplantation. Chest. 2017;152(3):627–38.CrossRefPubMed
31.
go back to reference Tiseo G, Brigante G, Giacobbe DR, Maraolo AE, Gona F, Falcone M. etal.Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian society of anti-infective therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical microbiologists (AMCLI) and the Italian Society of Microbiology (SIM).Int J Antimicrob Agents.2022;60(2):106611. Tiseo G, Brigante G, Giacobbe DR, Maraolo AE, Gona F, Falcone M. etal.Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian society of anti-infective therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical microbiologists (AMCLI) and the Italian Society of Microbiology (SIM).Int J Antimicrob Agents.2022;60(2):106611.
32.
go back to reference Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M. etal.ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia.Intensive Care Med.2023;1–18. Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M. etal.ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia.Intensive Care Med.2023;1–18.
33.
go back to reference Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG. etal.Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.2012;18(3):268–81. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG. etal.Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.2012;18(3):268–81.
34.
go back to reference Rossolini GM, Bochenska M, Fumagalli L, Dowzicky M. Trends of major antimicrobial resistance phenotypes in enterobacterales and gram-negative non-fermenters from ATLAS and EARS-net surveillance systems: Italian vs. European and global data, 2008–2018.Diagn Microbiol Infect Dis. 2021;101(4):115512. Rossolini GM, Bochenska M, Fumagalli L, Dowzicky M. Trends of major antimicrobial resistance phenotypes in enterobacterales and gram-negative non-fermenters from ATLAS and EARS-net surveillance systems: Italian vs. European and global data, 2008–2018.Diagn Microbiol Infect Dis. 2021;101(4):115512.
35.
go back to reference Paul M, Carrara E, Retamar P. etal.European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).Clin Microbiol Infect.2022;28(4):521–47. Paul M, Carrara E, Retamar P. etal.European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).Clin Microbiol Infect.2022;28(4):521–47.
36.
go back to reference Magiorakos A-P, Srinivasan A, Carey RB. etal.Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.Clin Microbiol Infect. 2012;18(3):268–81. Magiorakos A-P, Srinivasan A, Carey RB. etal.Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.Clin Microbiol Infect. 2012;18(3):268–81.
37.
go back to reference Nabal Diaz SG, Robles OA, Moya JMGL. New definitions of susceptibility categories EUCAST 2019: clinic application.Rev Esp Quimioter.2022;35(3):84–8. Nabal Diaz SG, Robles OA, Moya JMGL. New definitions of susceptibility categories EUCAST 2019: clinic application.Rev Esp Quimioter.2022;35(3):84–8.
38.
go back to reference (https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf). (https://​www.​cdc.​gov/​nhsn/​pdfs/​pscmanual/​17pscnosinfdef_​current.​pdf).
39.
go back to reference Avtaar Singh SS, Banner NR, Rushton S, Simon AR, Berry C, Al-Attar N. ISHLT primary graft dysfunction incidence, risk factors, and outcome: a UK National Study.Transplantation.2019;103(2):336–43. Avtaar Singh SS, Banner NR, Rushton S, Simon AR, Berry C, Al-Attar N. ISHLT primary graft dysfunction incidence, risk factors, and outcome: a UK National Study.Transplantation.2019;103(2):336–43.
40.
go back to reference Silva JT, Fernández-Ruiz M, Aguado JM. Multidrug-resistant Gram-negative infection in solid organ transplant recipients: implications for outcome and treatment.Curr Opin Infect Dis.2018;31(6):499–505. Silva JT, Fernández-Ruiz M, Aguado JM. Multidrug-resistant Gram-negative infection in solid organ transplant recipients: implications for outcome and treatment.Curr Opin Infect Dis.2018;31(6):499–505.
41.
go back to reference Jin M, Zeng L, Zhang W, Deng X, Li J, Zhang W. Clinical features of multidrug-resistant organism infections in early postoperative solid organ transplantation in a single center. Ann Palliat Med. 2021;10(4):4555–62.CrossRefPubMed Jin M, Zeng L, Zhang W, Deng X, Li J, Zhang W. Clinical features of multidrug-resistant organism infections in early postoperative solid organ transplantation in a single center. Ann Palliat Med. 2021;10(4):4555–62.CrossRefPubMed
Metadata
Title
Gram-negative bacterial colonizations before bilateral lung transplant. The impact of ‘targeted’ versus ‘standard’ surgical prophylaxis
Authors
Sabrina Congedi
Arianna Peralta
Luisa Muraro
Martina Biscaro
Tommaso Pettenuzzo
Nicolò Sella
Silvia Crociani
Arméla Anne-Sabine Tagne
Ida Caregnato
Francesco Monteleone
Elisa Rossi
Gabriella Roca
Silvia Manfrin
Serena Marinello
Maria Mazzitelli
Andrea Dell’Amore
Annamaria Cattelan
Federico Rea
Paolo Navalesi
Annalisa Boscolo
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09199-y

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine